Home / Health / AMERICA'S MEDICINE CABINET: Facing a Global Security Threat
AMERICA'S MEDICINE CABINET: Facing a Global Security Threat
2 Nov
Summary
- Antibiotic resistance caused 1.27 million direct deaths globally in 2019.
- US drug supply chain relies heavily on China for key ingredients.
- The Pasteur Act proposes $6 billion over 10 years for drug innovation funding.
Antibiotic resistance poses a significant national security threat to the United States, impacting modern medicine like chemotherapy and transplants. Resistant bacteria were directly linked to approximately 1.27 million deaths worldwide in 2019. The U.S. faces a critical dependency on foreign manufacturing, particularly China, for essential antibiotic ingredients, nearly half of the global supply.
A market failure occurs because antibiotic development is costly, with makers unable to recoup expenses due to resistance breeding with each use. This has led major pharmaceutical companies to exit antibiotic research. The U.S. government possesses solutions but has shown inertia.
The bipartisan Pasteur Act, introduced in 2020, offers a subscription model where the government pays a fixed annual fee for new antibiotics, ensuring developers receive predictable returns. This approach aims to keep vital drugs in reserve. Britain has already implemented similar contracts, but U.S. adoption is crucial for global impact.
A more cost-effective, yet neglected, reform involves reimbursing diagnostic tests that determine the necessity of antibiotics. Currently, unnecessary prescriptions account for about a third of outpatient antibiotic use. Implementing rapid tests and reimbursement policies could slow resistance and save money.
Additional measures include strategic reserves, diversified manufacturing, and international leadership in financing antibiotic innovation. These steps echo the U.S. mobilization for COVID-19 vaccines. While initial steps on supply-chain resilience have been taken by recent administrations, significant action is still required.
